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or PB blast >0%
No / No 77 35% Ref. 44% Ref. 46% Ref.
Yes / No 31 39% 0.1 28% 0.02 30% 0.01
No / Yes 117 50% 0.002 21% <0.001 23% <0.001
Yes / Yes 110 57% <0.001 14% <0.001 16% <0.001
Figure.
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Cytogenetics and Blast Count Determine Transplant
Outcomes in Advanced AML
Uday R. Popat, Rima Saliba, Betul Oran, Julianne Chen,
Amin M. Alousi, Sairah Ahmed, Qaiser Bashir,
Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Partow Kebriaei,
Issa F. Khouri, Yago L. Nieto, Amanda Olson, Simrit Parmar,
Nina Shah, Elizabeth J. Shpall, Muzaffar H. Qazilbash,
Borje S. Andersson, Richard E. Champlin. Stem Cell
Transplantation and Cellular Therapy, The University of Texas
MD Anderson Cancer Center, Houston, TX
Background: Patients with advanced AML, ie, those not in
ﬁrst (CR1) or second complete remission (CR2) have poor
outcome and are considered poor transplant candidates. The
purpose of this study was to identify a subgroup of patients
with active disease at the time of transplant that beneﬁts
from allogeneic transplantation.
Patients and Methods: Between 2005 and 2013, 782 pa-
tients underwent allogeneic transplant from a fully matched
(10/10) related or unrelated donor at our center. Of these 361
patients with advanced disease, deﬁned as patient not in CR1
or CR2, were included in this analysis. Cox proportional
hazards regression analysis was used for univariate and
multivariate analysis to predict overall survival. Variables
considered in the analysis were age, sex, SWOG cytogenetics
risk group, BM and PB blast%, regimen intensity (myelo-
ablative v/s reduced intensity) and type of AML (de novo,
secondary to MDS or MPD or therapy related AML).
Results: At a median follow up of 26 months in the surviving
patients, OS, PFS, NRM and relapse rate were 26%, 24%, 23%
and 48%, respectively. In a univariate analysis poor risk
cytogenetics (P<0.001) and bone marrow blasts >4%
(P 0.006) or any blasts in peripheral blood (P<.001) indicatedadverse outcome for OS. When poor risk cytogenetics and
peripheral and/or bone marrow blasts were considered
simultaneously (Table 1, ﬁg 1), signiﬁcantly superior survival
was observed in patients with less than 5% BM blasts without
any circulating blast and good or intermediate risk
cytogenetics. This impact was also seen for PFS and disease
progression. At 3 years PFS and OS were 44% and 46% in
this subgroup.
Conclusion: Patients with low blast counts in the absence of
poor-risk cytogenetics should be considered for transplant,
even if they are not in remission.438
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Cell requests for allogeneic bone marrow grafts are deﬁned
by the amount of total nucleated cells (TNC) according to
body weight of the recipient. However, outcome of bone
marrow transplantation signiﬁcantly depends on the
amount of infused CD34+ stem and progenitor cells repre-
senting around 0.5 to 1.5% of TNC. So far, TNC as well as the
CD34+ progenitor yield of marrow harvests cannot be pre-
dicted.We retrospectively analyzed donor variables, TNC and
progenitor yields of 1275 marrow collections (860 male and
415 female) that have been performed in our collection
center - all of those with same experienced staff of physi-
cians. Maximum amount of bone marrow that was allowed
to harvest was 20 ml/kg donor weight but limited to a
maximum of 1500 ml. The mean TNC count in the ﬁnal
product was analyzed with 16.6 TNC/nl (5.9-46.6) corre-
sponding to 5.6  4.3 TNC/kg body weight of the recipient.
The mean CD34+cell concentration in the graft was
measured with 111/ml (11-674) corresponding to 4.3  3.9
CD34+cells/kg. We ﬁtted linear regression model for TNC
adjusted for harvest volume and recipient weight to identify
inﬂuential donor variables. Model selection was performed
by backward elimination (BE) with the Bayesian information
criterion (BIC). Peripheral blood leucocytes of the donor
(WBC) before harvest, constitutional donor variables (weight
and height), age, platelet count (PLT), smoking status and
mononuclear cell count (MNC) before harvest could be
identiﬁed as predictive donor parameters for TNC-concen-
tration in the bone marrow product e ordered in descending
mode by Wald-test statistic. Interestingly, the inﬂuence of
donor parameters for CD34+ progenitor cell concentration in
the marrow was different from TNC. Constitutional param-
eters of the donor were identiﬁed to be most important for
CD34+ cell concentration in the marrow product followed by
WBC, age and PLT, whereas smoking status and MNC did not
inﬂuence CD34+ cell harvest. With sex speciﬁc centered
parameters donor sex was only inﬂuential - for both TNC as
well as CD34+ cells - through the constitutional parameters
weight and height. No signiﬁcant interactions could be found
between harvested volume and the identiﬁed donor pa-
rameters. Taking also the recipient weight into account we
propose a model that allows identiﬁcation of risk constella-
tions for achieving the designated amount of TNC as well as
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harvests. In addition, this prediction model will enable us to
identify additional genetic determinants for collection efﬁ-
ciency in bone marrow.439
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Background: Despite the progress of antiviral therapy in
recent years, CMV infection continues to be a major
complication after allogeneic hematopoietic cell trans-
plantation (HCT). We aimed to study the risk factors for ﬁrst
and subsequent CMV infections among patients who are
CMV seropositive.
Methods: we analyzed all sequential CMV seropositive pa-
tients that were given allogeneic HCT in a single center. We
tested the impact of a variety of patients and trans-
plantation’s characteristics on both ﬁrst and subsequent
CMV reactivations. Signiﬁcant factors identiﬁed on multi-
variate analyses were entered intomodels to predict ﬁrst and
subsequent CMV reactivation.
Results: Between May 2007 and December 2012, 121 CMV
seropositive patients were given allograft. Multivariate
model identiﬁed myeloablative preparative regimen
(HR¼4.297, p¼.033) and acute GVHD prior to infection
(HR¼5.091, p¼.021) as risk factors for ﬁrst CMV infection.
The cumulative incidences of ﬁrst CMV infection for patients
with 0, 1 and 2 risk factors were 52%, 71% and 91%, respec-
tively, Figure. Receiver operating curves for the model
showed for one risk factor a sensitivity of 84% and speciﬁcity
of 34% and for 2 risk factors 41% and 91%, respectively.
Multivariate analysis identiﬁed the diagnosis of lymphoma/
myeloma (HR¼3.5, p¼.049) and GVHD (HR¼1.280, p¼.045)
as risk factors for subsequent CMV infection. High graft CD3
stem cell dose was protective (HR¼0.543, p¼.056). The cu-
mulative incidences for subsequent CMV reactivation in pa-
tients with 0, 1, and 2-3 risk factors were 11%, 43% and 77%,
respectively. Receiver operating curves for the model
showed for one risk factor a sensitivity of 67% and speciﬁcity
of 90% and for more than 2 risk factors 93% and 47%,
respectively.Figure.Conclusions: In CMV seropositive patients, myeloablative
conditioning and acute GVHD are risk factors for ﬁrst CMV
infection and lymphoma/myeloma, ongoing GVHD and low
CD3 graft content are risk factors for a subsequent in-
fection.440
Unmanipulated Bone Marrow As Third Party Donor for
Unrelated Cord Blood Transplant Decreases 100-Day
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UCBT has high early transplant-related mortality. We
explored the feasibility of using related, mismatched, and
unmanipulated bone marrow as third party donor graft with
the addition of post-transplant cyclophosphamide (PtCy) for
unrelated single unit UCBT (dual transplants). Our aimwas to
decrease UCBT early mortality without increasing aGvHD.
We compared 16 cases of dual transplant (09/2012-08/14,
center 1) with two single UCBT historical groups; one with
PtCy (20 cases, 07/2010-08/12, center 1 & 2), and a 2nd
without PtCy (31 cases, 03/2010-07/12, center 2). We did not
include Fanconi and dyskeratosis congenita patients. The
main features of this dual platform were; 1. Pre-transplant
rATG (7 mg/kg/total dose) with Rituximab (100 mg/m2/total
dose), 2. Related bone marrow graft stimulated with 3 days
G-CSF and 3. PtCy on days +3 and +4 (100 mg/kg/total dose).
We used this core for bothmyeloablative (59%) and RIC UCBT.
In the ﬁrst 11 cases, CSA and MMF were started at day +5. In
the other 6 patients, we used sirolimus before transplant
(day -6) and MMF (day +5). To estimate adjusted hazards
rates (HR) by transplant group we carried out Cox’s multi-
variate regression models clustered by transplant year.
Covariates included in the models were: age, sex, RIC, HLA
match, CMV receptor status, pre-freezing total nucleated
cells (TNC), CD34, female:male receptor:donor mismatch.
Receptors in the dual group were older (median age (yrs)
12.1 vs 6.0 vs 6.7; P<0.01). Median CB TNC and CD34 cells
infused for dual, with and without PtCy were 5.7 vs 6.7 vs
5.4x107/kg (P¼0.08), and 2.2 vs 2.7 vs 2.7x105/kg (P¼0.45),
respectively. Dual, PtCy, and non-PtCy groupsmedian time to
neutrophil and platelet engraftment was 18.5 vs 25 vs 17
days (P¼0.07), and 19 vs 40.5 vs 33 (P¼0.01), respectively.
Grades II-IV aGvHD for each group was 47%, 31%, and 56%
(P¼0.30). There were no cases of grade IV aGvHD in the dual
or the PtCy group. Acute leukemia 12 months cumulative
relapse was 6% for dual compared with the other 2 groups
(32% and 33%, P¼0.12). Cumulative 100-daymortality was 7%
for dual compared with 23% and 28% for the other two co-
horts (P¼0.1). Using the non-PtCy cohort as referent, 100-day
mortality HR was 0.2 (95%CI: 0.1, 0.6) for dual and 0.9 (95%CI:
0.2, 5.2) for the PtCy group. One-year HR was 0.6 (95%CI: 0.3,
1.5) for dual, and 0.9 (95%CI: 0.3, 2.9) for the PtCy group.
Overall, PtCy-dual transplant approach decreases 100-day
